Biodesix said on Thursday that it has priced a public offering of 30.5 million shares of its stock at $1.15 apiece for expected gross proceeds of $35.1 million.

Burning Rock Biotech said late Tuesday that its Q3 revenues were up 22 percent year over year, driven by higher volumes of the companies test kits for use in hospitals.

Precision oncology company Novigenix said on Wednesday the successful first closing of a $20 million Series B round.

The US Food and Drug Administration said on Tuesday that it has granted Emergency Use Authorization for Roche's molecular monkeypox test.

Ginkgo Bioworks said after the close of the market on Monday that it has raised its full-year 2022 revenue guidance to between $460 million and $480 million, up from previous guidance of between $425 million and $440 million, driven by strength in the firm's biosecurity business.

PerkinElmer said Monday it had secured US Food and Drug Administration authorization to market an assay for the simultaneous detection of spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns.

SomaLogic reported on Monday that it has recorded a one-time licensing royalty of $21.2 million related to a deal with New England Biolabs.

Roche has begun over-the-counter sales of its at-home COVID-19 rapid antigen test in the U.S.

GE HealthCare has priced an offering of $8.25 billion senior notes in conjunction with the spinoff from its parent company.

Recently, EasyDiagnosis disclosed its third quarterly report, the company achieved revenue of 7.47 billion CNY in the first three quarters, an increase of 285.38% year-on-year; achieved net profit of 3.838 billion CNY, an increase of 281.76% year-on-year.

Becton Dickinson Fiscal Q4 Revenues Decline 2 Percent

The US Food and Drug Administration this week granted Emergency Use Authorization for Nanobiosym Precision Testing Services' Nano Test for COVID-19.

The US Food and Drug Administration last week granted Emergency Use Authorization for Rize Laboratory's SARS nCoV-2019 Multiplexed Assay.

Italian diagnostics firm DiaSorin said on Wednesday that it has received 510(k) clearance from the US Food and Drug Administration for its Simplexa Congenital CMV Direct kit for the detection of cytomegalovirus (CMV) DNA.

Wondfo (300482.SZ) released its third quarter report for 2022. The company's revenue in the first three quarters was CNY 4.696 billion, up 87.32% year-on-year; net profit attributable to the mother company was CNY 1.240 billion